Utilizing targeted CXCR4 inhibitors mobilizes hematologic tumor cells from the bone marrow into peripheral circulation, enabling effective eradication by chemotherapy agents, small-molecule inhibitors, or demethylation agents. This evidence concerns the gene CXCR4 and neoplasm.